Edwards Lifesciences (EW) Operating Leases (2019 - 2026)

Edwards Lifesciences' Operating Leases history runs 8 years deep, the most recent figure standing at $80.1 million for Q1 2026.

• On a quarterly basis, Operating Leases rose 2.82% year-over-year to $80.1 million in Q1 2026; TTM through Mar 2026 was $80.1 million, a 2.82% increase from a year earlier, with the FY2025 full-year figure at $82.6 million, up 4.69% from the prior year.
• Operating Leases declined to $80.1 million in Q1 2026 per EW's latest filing, from $82.6 million in the prior quarter.
• Across five years, Operating Leases topped out at $88.1 million in Q4 2023 and bottomed at $63.5 million in Q2 2022.
• The 5-year median for Operating Leases is $75.3 million (2025), against an average of $74.5 million.
• Across the five-year window, Operating Leases retreated 26.53% in 2022 and increased 26.76% in 2023, its largest moves.
• Year by year, Operating Leases stood at $69.5 million in 2022, then gained by 26.76% to $88.1 million in 2023, then slipped by 10.44% to $78.9 million in 2024, then grew by 4.69% to $82.6 million in 2025, then decreased by 3.03% to $80.1 million in 2026.
• Per Business Quant, the three latest EW Operating Leases figures stand at $80.1 million (Q1 2026), $82.6 million (Q4 2025), and $75.3 million (Q3 2025).